Immunotherapy for resectable NSCLC: neoadjuvant/perioperative followed by surgery over surgery followed by adjuvant. Systematic review and meta-analysis with subgroup analyses
Our results indicate that neoadjuvant/perioperative immunotherapy should be considered the standard. This should be preferred over upfront surgery, also in stage II, PD-L1-negative and squamous histology.
Authors
- Enrica T. Tanda (ORCID: https://orcid.org/0000-0002-1552-9826)
- Eva Blondeaux (ORCID: https://orcid.org/0000-0001-9566-4579)
- Giovanni Rossi (ORCID: https://orcid.org/0000-0001-8432-5408)
- Francesco Spagnolo (ORCID: https://orcid.org/0000-0003-3287-1225)
- Lucrezia Barcellini
- Marco Tagliamento (ORCID: https://orcid.org/0000-0001-7461-023X)
- Lucia Del Mastro (ORCID: https://orcid.org/0000-0002-9546-5841)
- Carlo Genova (ORCID: https://orcid.org/0000-0003-3690-8582)
- Virginia Delucchi
- Marina Chiara Garassino
Institutions
- University of Chicago (US)
- Ospedale Policlinico San Martino (IT)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105759
- Citations
- 6
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 9.11